advertisement
Abstract #69176 Published in IGR 18-1
Effects of a dorzolamide/timolol fixed combination on diurnal intraocular pressure, heart rate, blood pressure, and ocular perfusion pressure in normal-tension glaucoma
Lee NY; Park HY; Park CKJapanese Journal of Ophthalmology 2016; 60: 377-382
PURPOSE: The aim of this study was to evaluate the effects of a dorzolamide-timolol fixed combination (DTFC) on intraocular pressure (IOP), heart rate (HR), blood pressure (BP), ocular perfusion pressure (OPP), and diastolic ocular perfusion pressure (DOPP) in patients with normal-tension glaucoma (NTG). METHODS: A prospective, interventional, single-blind, single-center study was conducted. Newly diagnosed NTG patients that had not been treated with a glaucoma medication in the most recent 4Â weeks were included. Patients were examined at baseline (without medication) and week 4 (under medication). Baseline IOP, HR, systolic and diastolic BP, OPP, and DOPP were measured at 8Â am, 12Â pm, and 4Â pm. At week 4, IOP, HR, systolic and diastolic BP, OPP, and DOPP were measured at 10Â am and 8Â pm as well. RESULTS: After 4Â weeks of DTFC treatment, IOP was significantly reduced at all time points (1.6-2.6Â mmHg, PÂ <Â 0.001), and the average IOP reduction was 14.4Â %. HR and systolic BP showed no statistically significant difference at all time points; however, diastolic BP was decreased significantly at 12Â pm and 4Â pm (PÂ =Â 0.004 and 0.001). OPP and DOPP showed no statistical significant difference after DTFC. CONCLUSIONS: DTFC has favorable effects on IOP and can be used without concerns of DOPP in patients with NTG.
Full article
Classification:
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)
6.1.2 Fluctuation, circadian rhythms (Part of: 6 Clinical examination methods > 6.1 Intraocular pressure measurement; factors affecting IOP)
6.11 Bloodflow measurements (Part of: 6 Clinical examination methods)
